ERBB2 and breast carcinoma: As per the mechanism of TZM’s anticancer activity, it is a humanized monoclonal antibody directed against human epidermal growth factor receptor 2 (HER2) [415].The incidence of adverse cardiac effects in patients with breast cancer treated with TZM differs among clinical trials and dosage regimens and ranges from 0.7% to 7.25% [416, 417].